Cargando…

Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy

Patients with central serous chorioretinopathy (CSC) often complain of visual difficulties under low luminance conditions. In this study, we evaluated low luminance visual acuity (LLVA) after half-dose verteporfin photodynamic therapy (hdPDT) in eyes with CSC. The study included eight eyes of eight...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Kyoko, Shinoda, Kei, Imamura, Yutaka, Matsumoto, Celso Soiti, Oda, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764769/
https://www.ncbi.nlm.nih.gov/pubmed/33316889
http://dx.doi.org/10.3390/jcm9123980
_version_ 1783628335350284288
author Fujita, Kyoko
Shinoda, Kei
Imamura, Yutaka
Matsumoto, Celso Soiti
Oda, Koichi
author_facet Fujita, Kyoko
Shinoda, Kei
Imamura, Yutaka
Matsumoto, Celso Soiti
Oda, Koichi
author_sort Fujita, Kyoko
collection PubMed
description Patients with central serous chorioretinopathy (CSC) often complain of visual difficulties under low luminance conditions. In this study, we evaluated low luminance visual acuity (LLVA) after half-dose verteporfin photodynamic therapy (hdPDT) in eyes with CSC. The study included eight eyes of eight patients with chronic CSC that underwent hdPDT. The best-corrected visual acuity, LLVA and optical coherence tomography (OCT) findings were evaluated at baseline, and at 1, 3, 6, 9, and 12 months after hdPDT. LLVA was measured at six levels of background luminance. Serous retinal detachment was completely resolved in all eyes. Although the mean LLVA at 1 month did not improve significantly compared to baseline at all luminance levels, significant improvements were observed at 3, 6, 9, and 12 months (p < 0.05). In OCT images, although the ellipsoid zone was not detectable in all eyes before hdPDT, it was observed in 2 eyes at 1 month, in 7 eyes at 3 months, and in all eyes from 6 months. The LLVA and the ellipsoid zone improved similarly with postoperative time courses. In conclusion, hdPDT improves LLVA in eyes with chronic CSC. The recovery of the ellipsoid zone may play a part in improving LLVA after hdPDT.
format Online
Article
Text
id pubmed-7764769
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77647692020-12-27 Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy Fujita, Kyoko Shinoda, Kei Imamura, Yutaka Matsumoto, Celso Soiti Oda, Koichi J Clin Med Article Patients with central serous chorioretinopathy (CSC) often complain of visual difficulties under low luminance conditions. In this study, we evaluated low luminance visual acuity (LLVA) after half-dose verteporfin photodynamic therapy (hdPDT) in eyes with CSC. The study included eight eyes of eight patients with chronic CSC that underwent hdPDT. The best-corrected visual acuity, LLVA and optical coherence tomography (OCT) findings were evaluated at baseline, and at 1, 3, 6, 9, and 12 months after hdPDT. LLVA was measured at six levels of background luminance. Serous retinal detachment was completely resolved in all eyes. Although the mean LLVA at 1 month did not improve significantly compared to baseline at all luminance levels, significant improvements were observed at 3, 6, 9, and 12 months (p < 0.05). In OCT images, although the ellipsoid zone was not detectable in all eyes before hdPDT, it was observed in 2 eyes at 1 month, in 7 eyes at 3 months, and in all eyes from 6 months. The LLVA and the ellipsoid zone improved similarly with postoperative time courses. In conclusion, hdPDT improves LLVA in eyes with chronic CSC. The recovery of the ellipsoid zone may play a part in improving LLVA after hdPDT. MDPI 2020-12-09 /pmc/articles/PMC7764769/ /pubmed/33316889 http://dx.doi.org/10.3390/jcm9123980 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fujita, Kyoko
Shinoda, Kei
Imamura, Yutaka
Matsumoto, Celso Soiti
Oda, Koichi
Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
title Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
title_full Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
title_fullStr Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
title_full_unstemmed Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
title_short Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
title_sort improvement of low luminance visual acuity in patients with chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764769/
https://www.ncbi.nlm.nih.gov/pubmed/33316889
http://dx.doi.org/10.3390/jcm9123980
work_keys_str_mv AT fujitakyoko improvementoflowluminancevisualacuityinpatientswithchroniccentralserouschorioretinopathyafterhalfdoseverteporfinphotodynamictherapy
AT shinodakei improvementoflowluminancevisualacuityinpatientswithchroniccentralserouschorioretinopathyafterhalfdoseverteporfinphotodynamictherapy
AT imamurayutaka improvementoflowluminancevisualacuityinpatientswithchroniccentralserouschorioretinopathyafterhalfdoseverteporfinphotodynamictherapy
AT matsumotocelsosoiti improvementoflowluminancevisualacuityinpatientswithchroniccentralserouschorioretinopathyafterhalfdoseverteporfinphotodynamictherapy
AT odakoichi improvementoflowluminancevisualacuityinpatientswithchroniccentralserouschorioretinopathyafterhalfdoseverteporfinphotodynamictherapy